Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.64 |
| ▸ | GAA | P10253 | 3/20 | 0.64 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | NAMPT | P43490 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21986228 | 0.85 | POLB (0.64) | ALDH1A1SMN1; SMN2GAAPOLBMEN1 | |
| SCHEMBL13417649 | 0.83 | ATM (0.57) | ALDH1A1SMN1; SMN2POLBLMNATSHR | |
| SCHEMBL31372420 | 0.81 | ALDH1A1 (0.67) | ALDH1A1SMN1; SMN2GAAPOLBLMNA | |
| SCHEMBL3149654 | 0.81 | POLB (0.72) | ALDH1A1SMN1; SMN2GAAPOLBLMNA | |
| SCHEMBL19951018 | 0.81 | ALDH1A1 (0.67) | ALDH1A1SMN1; SMN2GAAPOLBLMNA | |
| SCHEMBL30693019 | 0.81 | POLB (0.72) | ALDH1A1SMN1; SMN2GAAPOLBLMNA | |
| SCHEMBL8817799 | 0.81 | ALDH1A1 (0.62) | ALDH1A1SMN1; SMN2GAAPOLBLMNA | |
| SCHEMBL12793245 | 0.79 | POLB (0.88) | ALDH1A1SMN1; SMN2GAAPOLBLMNA | |
| SCHEMBL10306750 | 0.78 | POLB (0.73) | ALDH1A1SMN1; SMN2GAAPOLBLMNA | |
| SCHEMBL171151 | 0.78 | POLB (0.73) | ALDH1A1SMN1; SMN2GAAPOLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023235925-A1 | COMPOUNDS WITH MERTK ACTIVITY | MONASH UNIVERSITY (AU) | 2023-12-14 | — | — | WO | disclosed |
| US-9309240-B2 | Pyrazolopyridine compounds, compositions and methods of use | GENENTECH, INC. (US) | 2016-04-12 | — | — | US | disclosed |
| EP-2640722-B1 | PYRAZOLOPYRIDINES AND THEIR USE AS TYK2 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2015-11-04 | — | — | EP | disclosed |
| US-20130252941-A1 | PYRAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-09-26 | — | — | US | disclosed |
| WO-2012022265-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND USES THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2012-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130252941-A1 | PYRAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | P2RX5, P2RX4, P2RY1 | ALDH1A1 1091/4885SMN1; SMN2 2102/4885GAA 3826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.